A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.

MLA

Moreno-González, G., et al. “A Phase I/II Clinical Trial to Evaluate the Efficacy of Baricitinib to Prevent Respiratory Insufficiency Progression in Onco-Hematological Patients Affected with COVID19: A Structured Summary of a Study Protocol for a Randomised Controlled Trial.” Trials, vol. 22, no. 1, Feb. 2021, pp. 1–4. EBSCOhost, https://doi.org/10.1186/s13063-021-05072-4.

APA

Moreno-González, G., Mussetti, A., Albasanz-Puig, A., Salvador, I., Sureda, A., Gudiol, C., Salazar, R., Marin, M., Garcia, M., Navarro, V., de la Haba Vaca, I., Coma, E., Sanz-Linares, G., Dura, X., Fontanals, S., Serrano, G., Cruz, C., & Mañez, R. (2021). A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. Trials, 22(1), 1–4. https://doi.org/10.1186/s13063-021-05072-4

Chicago

Moreno-González, G., A. Mussetti, A. Albasanz-Puig, I. Salvador, A. Sureda, C. Gudiol, R. Salazar, et al. 2021. “A Phase I/II Clinical Trial to Evaluate the Efficacy of Baricitinib to Prevent Respiratory Insufficiency Progression in Onco-Hematological Patients Affected with COVID19: A Structured Summary of a Study Protocol for a Randomised Controlled Trial.” Trials 22 (1): 1–4. doi:10.1186/s13063-021-05072-4.